Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal aflibercept in treatment-resistant pigment epithelial detachment

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

The purpose of the study was to assess the efficacy and safety of transition from ranibizumab to aflibercept intravitreal injections in treatment-resistant retinal pigment epithelial detachment (PED). The data of intravitreal ranibizumab treatment-resistant patients who have been switched to aflibercept treatment were reviewed retrospectively. After three monthly injections, bimonthly regimen was performed. The changes of PED height and radius, and the best-corrected visual acuity (BCVA) were analyzed retrospectively. Mean baseline PED height decreased from 297 ± 151 to 122 ± 42 µm at month 12 (P = 0.0007). Mean baseline PED radius decreased from 2371 ± 882 to 1859 ± 779 µm at month 12 (P = 0.0007). No complete PED resolution occurred in any of the patients at the end of the 12 months. Baseline BCVA improved from 0.63 ± 0.21 to 0.43 ± 0.17 logMar at month 12 (P = 0.0049). Mean BCVA gain was 1.4 decimal chart lines (7 letters) at month 12. Switching to aflibercept seems to have promising functional and anatomical outcomes with a reasonable complication rate in treatment-resistant PED.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zayit-Soudry S, Moroz I, Loewenstein A (2007) Retinal pigment epithelial detachment. Surv Ophthalmol 52(3):227–243

    Article  PubMed  Google Scholar 

  2. Roquet W, Roudot-Thoraval F, Coscas G, Soubrane G (2004) Clinical features of drusenoid pigment epithelial detachment in age related macular degeneration. Br J Ophthalmol 88(5):638–642

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Iordanous Y, Powell AM, Mao A, Hooper PL, Eng KT, Schwartz C, Kertes PJ, Sheidow TG (2014) Intravitreal ranibizumab for the treatment of fibrovascular pigment epithelial detachment in age-related macular degeneration. Can J Ophthalmol 49(4):367–376. doi:10.1016/j.jcjo.2014.05.010

    Article  PubMed  Google Scholar 

  4. Murphy RP, Yeo JH, Green WR et al (1985) Dehiscences of the pigment epithelium. Trans Am Ophthalmol Soc 83:63–81

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Mrejen S, Sarraf D, Mukkamala SK, Freund KB (2013) Multimodal imaging of pigment epithelial detachment: a guide to evaluation. Retina 33:1735–1762

    Article  PubMed  Google Scholar 

  6. Yannuzzi LA (1989) Retinal pigment epithelial detachment. J Fr Ophtalmol 12:761–774

    CAS  PubMed  Google Scholar 

  7. Abdelfattah NS, Sadda SR (2015) Dry AMD progression in wet AMD: what we know and don’t know about geographic atrophy. Retina Specialist 6(June):18–21

    Google Scholar 

  8. Gelisken F, Inhoffen W, Partsch M et al (2001) Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am J Ophthalmol 131:518–520

    Article  CAS  PubMed  Google Scholar 

  9. Weinberger AW, Thiel M, Mohammadi B et al (2007) Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 144(2):294–296

    Article  CAS  PubMed  Google Scholar 

  10. Lommatzsch A, Heimes B, Gutfleisch M et al (2009) Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye 23(12):2163–2168

    Article  CAS  PubMed  Google Scholar 

  11. Brown DM, Kaiser PK, Michels M, ANCHOR Study Group et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444

    Article  CAS  PubMed  Google Scholar 

  12. Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431

    Article  CAS  PubMed  Google Scholar 

  13. Fung AE, Lalwani GA, Rosenfeld PJ et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583

    Article  CAS  PubMed  Google Scholar 

  14. Broadhead GK, Hong T, Zhu M, Li H, Schlub TE, Wijeyakumar W, Chang AA (2015) Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina 35(5):975–981. doi:10.1097/IAE.0000000000000409

    Article  CAS  PubMed  Google Scholar 

  15. Abdelfattah NS, Zhang H, Boyer DS, Sadda SR. (2016) Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy. Retina 2016 Apr 28. [Epub ahead of print]

  16. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121(1):193–201. doi:10.1016/j.ophtha.2013.08.011

    Article  PubMed  Google Scholar 

  17. Carmeliet P, Moons L, Luttun A et al (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7(5):575–583

  18. Autiero M, Luttun A, Tjwa M, Carmeliet P (2003) Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 1(7):1356–1370

    Article  CAS  PubMed  Google Scholar 

  19. Kumar N, Marsiglia M, Mrejen S et al (2013) Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33:1605–1612

  20. Patel KH, Chow CC, Rathod R et al (2013) Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye 27:663–667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Punjabi OS, Huang J, Rodriguez L et al (2013) Imaging characteristics of neovascular pigment epithelial detachments and their response to anti-vascular endothelial growth factor therapy. Br J Ophthalmol 97:1024–1031

    Article  PubMed  Google Scholar 

  22. Goldstein M, Heilweil G, Barak A, Loewenstein A (2005) Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD. Eye 19(12):1315–1324

    Article  CAS  PubMed  Google Scholar 

  23. Pece A, Introini U, Bottoni F et al (2001) Acute retinal pigment epithelial tear after photodynamic therapy. Retina 21:661–665

    Article  CAS  PubMed  Google Scholar 

  24. Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR (2015) TREX-AMD study group prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122(12):2514–2522. doi:10.1016/j.ophtha.2015.08.009

    Article  PubMed  Google Scholar 

  25. Major JC Jr, Wykoff CC, Croft DE, Wang R, Mariani AF, Lehmann AE, Brown DM (2015) Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. Can J Ophthalmol. 50(5):373–377. doi:10.1016/j.jcjo.2014.12.012

    Article  PubMed  Google Scholar 

  26. He L, Silva RA, Moshfeghi DM, Blumenkranz MS, Leng T (2016) Aflibercept for the treatment of retinal pigment epithelial detachments. Retina. 36(3):492–498. doi:10.1097/IAE.0000000000000749

    Article  CAS  PubMed  Google Scholar 

  27. Kanesa-Thasan A, Grewal DS, Gill MK, Lyon AT, Mirza R (2015) Quantification of change in pigment epithelial detachment volume and morphology after transition to intravitreal aflibercept in eyes with recalcitrant neovascular AMD: 18-month results. Ophthalmic Surg Lasers Imaging Retina 46(6):638–641. doi:10.3928/23258160-20150610-07

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ophthalmology Department, Medipol University, Bagcılar, Istanbul, Turkey

    Ibrahim Kocak

Authors
  1. Ibrahim Kocak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ibrahim Kocak.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kocak, I. Intravitreal aflibercept in treatment-resistant pigment epithelial detachment. Int Ophthalmol 37, 531–537 (2017). https://doi.org/10.1007/s10792-016-0294-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-016-0294-4

Keywords

Search

Navigation